DRUG
Price
$42.95
Change
+$0.78 (+1.85%)
Updated
Nov 14 closing price
PHGUF
Price
$0.82
Change
-$0.00 (-0.00%)
Updated
Oct 17 closing price
Ad is loading...

DRUG vs PHGUF

Header iconDRUG vs PHGUF Comparison
Open Charts DRUG vs PHGUFBanner chart's image
Bright Minds Biosciences
Price$42.95
Change+$0.78 (+1.85%)
Volume$216.85K
CapitalizationN/A
Pharming Group
Price$0.82
Change-$0.00 (-0.00%)
Volume$200
CapitalizationN/A
DRUG vs PHGUF Comparison Chart
Loading...
View a ticker or compare two or three
VS
DRUG vs. PHGUF commentary
Nov 15, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DRUG is a Sell and PHGUF is a Hold.

COMPARISON
Comparison
Nov 15, 2024
Stock price -- (DRUG: $42.95 vs. PHGUF: $0.82)
Brand notoriety: DRUG and PHGUF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DRUG: 5% vs. PHGUF: 35%
Market capitalization -- DRUG: $300.09M vs. PHGUF: $513.44M
DRUG [@Biotechnology] is valued at $300.09M. PHGUF’s [@Biotechnology] market capitalization is $513.44M. The market cap for tickers in the [@Biotechnology] industry ranges from $475.76B to $0. The average market capitalization across the [@Biotechnology] industry is $2.73B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DRUG’s FA Score shows that 0 FA rating(s) are green whilePHGUF’s FA Score has 1 green FA rating(s).

  • DRUG’s FA Score: 0 green, 5 red.
  • PHGUF’s FA Score: 1 green, 4 red.
According to our system of comparison, both DRUG and PHGUF are a bad buy in the long-term.

Price Growth

DRUG (@Biotechnology) experienced а -11.48% price change this week, while PHGUF (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.07%. For the same industry, the average monthly price growth was +3.27%, and the average quarterly price growth was +5.23%.

Reported Earning Dates

DRUG is expected to report earnings on Aug 28, 2023.

Industries' Descriptions

@Biotechnology (-2.07% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

FUNDAMENTALS
Fundamentals
PHGUF($513M) has a higher market cap than DRUG($300M). DRUG YTD gains are higher at: 2903.497 vs. PHGUF (-29.991).
DRUGPHGUFDRUG / PHGUF
Capitalization300M513M58%
EBITDAN/A7.56M-
Gain YTD2903.497-29.991-9,681%
P/E RatioN/AN/A-
RevenueN/A286M-
Total CashN/A172M-
Total DebtN/A127M-
FUNDAMENTALS RATINGS
PHGUF: Fundamental Ratings
PHGUF
OUTLOOK RATING
1..100
33
VALUATION
overvalued / fair valued / undervalued
1..100
79
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
92
PRICE GROWTH RATING
1..100
75
P/E GROWTH RATING
1..100
18
SEASONALITY SCORE
1..100
75

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
RSI
ODDS (%)
Stochastic
ODDS (%)
Momentum
ODDS (%)
MACD
ODDS (%)
TrendWeek
ODDS (%)
TrendMonth
ODDS (%)
Advances
ODDS (%)
Declines
ODDS (%)
BollingerBands
ODDS (%)
Aroon
ODDS (%)
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GME27.370.91
+3.44%
GameStop Corp
AAPL228.223.10
+1.38%
Apple
SPY593.35-3.84
-0.64%
SPDR® S&P 500® ETF Trust
BTC.X87250.430000-3333.734400
-3.68%
Bitcoin cryptocurrency
TSLA311.18-19.06
-5.77%
Tesla

DRUG and

Correlation & Price change

A.I.dvisor indicates that over the last year, DRUG has been loosely correlated with PHMMF. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if DRUG jumps, then PHMMF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DRUG
1D Price
Change %
DRUG100%
+1.85%
PHMMF - DRUG
44%
Loosely correlated
N/A
LBPH - DRUG
35%
Loosely correlated
-0.07%
ATYR - DRUG
32%
Poorly correlated
-9.37%
SEER - DRUG
29%
Poorly correlated
+4.76%
PHGUF - DRUG
28%
Poorly correlated
N/A
More

PHGUF and

Correlation & Price change

A.I.dvisor tells us that PHGUF and DRUG have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PHGUF and DRUG's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PHGUF
1D Price
Change %
PHGUF100%
N/A
DRUG - PHGUF
28%
Poorly correlated
+1.85%
ADXN - PHGUF
25%
Poorly correlated
-4.98%
SGMO - PHGUF
25%
Poorly correlated
-11.89%
XFOR - PHGUF
25%
Poorly correlated
+47.85%
CGTX - PHGUF
22%
Poorly correlated
-4.75%
More